Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report - Seite 2

• Delivered our innovative medicines to >2,600 individuals worldwide through commercial, clinical, and expanded access programs at the end of 2023.
• Collaborated with internal and external stakeholders on strengthening health equity in our clinical trials and the rare disease space.

Employees. Progressed and enhanced our transparent, inclusive, and collaborative culture to give employees the tools and resources to grow personally and professionally while ensuring we can meaningfully engage with the global rare disease community.

• Continued efforts to support employee development, advancement, and retention through our robust learning and leadership development programs.
• In February 2024, Amicus was certified as a Great Place to Work in the United States, United Kingdom, Italy, Germany, Spain, France, and Japan.

Governance. Maintained a strong culture of business ethics and integrity to ensure that the Company is managed for the long-term benefit of all our stakeholders.

• Amicus Board of Directors recognized by The Forum of Executive Women as a 2023 Champion of Board Diversity for having a Board of Directors where women account for more than 30% of the Board.
• 100% of employees received annual training on the Global Code of Conduct, data protection cybersecurity, and social media.
• Robust Board oversight of risk and the Enterprise Risk Management Program.
  

To access the full 2024 ESG Report, please visit www.amicusrx.com/responsibility/environmental-social-governance/.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information, please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
[e-mail]
[phone]

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
[e-mail]
[phone]

FOLD-G